Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | ARAF | P10398 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | MUSK | O15146 | 1/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478377 | 0.93 | RAF1 (0.86) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL549001 | 0.90 | RAF1 (1.00) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL937568 | 0.90 | RAF1 (1.00) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL548328 | 0.86 | RAF1 (0.79) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL2507080 | 0.84 | RAF1 (0.75) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL13471762 | 0.83 | RAF1 (0.84) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL1506420 | 0.83 | RAF1 (0.86) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL14481765 | 0.83 | RAF1 (0.86) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL5082237 | 0.82 | RAF1 (0.83) | RAF1KDRPDGFRBGSK3BARAF | |
| SCHEMBL20909069 | 0.82 | RAF1 (0.82) | RAF1KDRPDGFRBGSK3BARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | RAF1 51/4885KDR 44/4885PDGFRB 25/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | RAF1 4118/4885KDR 2385/4885PDGFRB 3206/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | RAF1 817/4885KDR 3/4885PDGFRB 137/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.